Physician profile
George Mark Schwartze
NPI 1376526251
$10,289.08
in general payments reported to CMS, 2019-2025
50 companies · $2,504 in 2025
The $2,504 reported for 2025 was more than what 95% of Neuromusculoskeletal Medicine & Omm providers received nationally (typical 2025 total: $119).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,152 · 2020: $1,507 · 2021: $1,327 · 2022: $956 · 2023: $1,608 · 2024: $1,235 · 2025: $2,504.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,312 · Honoraria: $35.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,311.51 |
| Honoraria | $35.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,597.44 | 2021-2025 | Qulipta, Ubrelvy, Botox |
| Amgen INC. | $1,030.04 | 2019-2025 | Aimovig, Uplizna |
| Biogen, INC. | $964.65 | 2019-2025 | Vumerity, Tysabri, Skyclarys |
| Lilly USA, LLC | $799.31 | 2020-2025 | Kisunla, Amyvid, Emgality |
| Novartis Pharmaceuticals Corporation | $711.37 | 2019-2025 | |
| Ucb, INC. | $699.86 | 2019-2025 | Briviact, Zilbrysq, Rystiggo |
| Emd Serono, INC. | $436.84 | 2019-2023 | Mavenclad |
| Medtronic Vascular, INC. | $334.36 | 2019-2020 | |
| Sk Life Science, INC. | $330.38 | 2021-2025 | |
| Supernus Pharmaceuticals, INC. | $319.12 | 2019-2021 | |
| Pfizer INC. | $310.24 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $225.64 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Acadia Pharmaceuticals INC | $204.85 | 2021-2025 | Nuplazid |
| Allergan, INC. | $187.93 | 2020-2022 | |
| Axsome Therapeutics, INC. | $173.72 | 2025 | Symbravo |
Show all 50 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $167.11 | 2023-2025 | |
| Lundbeck LLC | $149.81 | 2021-2025 | Vyepti |
| Medtronic, INC. | $131.74 | 2023-2024 | Intellis Adaptivestim, Vanta Adaptivestim, Synchromedii |
| Genzyme Corporation | $114.74 | 2020-2025 | |
| Argenx US, INC. | $108.75 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
| Mdd US Operations, LLC | $97.02 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $85.33 | 2021 | |
| Averitas Pharma INC. | $83.56 | 2025 | Qutenza |
| Livanova USA, INC. | $80.69 | 2023 | Vns Therapy Sentiva Model 1000 Generator |
| Biohaven Pharmaceutical Holding Company Ltd. | $79.69 | 2022 | |
| Acorda Therapeutics, INC | $64.88 | 2019-2024 | Inbrija |
| Genentech USA, INC. | $61.98 | 2024-2025 | Ocrevus Zunovo, Ocrevus |
| Arbor Pharmaceuticals, INC. | $61.18 | 2019-2021 | |
| Cycle Pharmaceuticals INC | $54.54 | 2024-2025 | Tascenso Odt |
| Stryker Corporation | $45.15 | 2022-2025 | Universal Neuro 3 |
| Neurocrine Biosciences, INC. | $43.58 | 2024-2025 | Ingrezza |
| Xeris Pharmaceuticals, INC. | $41.68 | 2022-2023 | Keveyis |
| Janssen Pharmaceuticals, INC | $37.31 | 2022 | |
| Sunovion Pharmaceuticals INC. | $37.25 | 2020-2021 | |
| Jazz Pharmaceuticals INC. | $36.61 | 2025 | |
| Natus Medical Incorporated | $35.54 | 2025 | |
| Siemens Medical Solutions USA, INC. | $35.48 | 2022 | |
| Celgene Corporation | $33.93 | 2025 | Zeposia |
| Springworks Therapeutics, INC. | $32.53 | 2025 | Gomekli |
| Avion Pharmaceuticals | $30.25 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $26.83 | 2024 | Exparel, Zilretta, Iovera |
| Corium, LLC | $26.38 | 2023 | Adlarity |
| Alexion Pharmaceuticals, INC. | $23.96 | 2019 | |
| Amneal Pharmaceuticals LLC | $23.62 | 2019-2020 | |
| Tg Therapeutics, INC. | $23.57 | 2024 | |
| Adamas Pharmaceuticals, INC. | $23.45 | 2020 | |
| Mallinckrodt Hospital Products INC. | $22.57 | 2021 | |
| Kyowa Kirin, INC. | $17.82 | 2024 | Nourianz |
| Impel Pharmaceuticals INC. | $17.61 | 2022 | |
| Life Molecular Imaging Ltd | $7.19 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Schwartze listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.